Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1373 ARTÍCULOS , VIENDO DEL 91 AL 105

Progress in Alzheimer's disease research in the last year

Galimberti D, Scarpini E.

J Neurol. 2013 Jul;260(7):1936-41. doi: 10.1007/s00415-013-6921-3. Epub 2013 Apr 18.

New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors

Greig NH, Reale M, Tata AM.

Recent Pat CNS Drug Discov. 2013 Aug;8(2):123-41. doi: 10.2174/1574889811308020003.

Apolipoprotein E, neurodegeneration, and Alzheimer disease

Jagust W.

JAMA Neurol. 2013 Mar 1;70(3):299-300. doi: 10.1001/jamaneurol.2013.726.

Targeting ubiquilin-1 in Alzheimer's disease

Takalo M, Haapasalo A, Natunen T, Viswanathan J, Kurkinen KM, Tanzi RE, Soininen H, Hiltunen M.

Expert Opin Ther Targets. 2013 Jul;17(7):795-810. doi: 10.1517/14728222.2013.791284. Epub 2013 Apr 21.

Role of metal ions in the self-assembly of the Alzheimer's amyloid-β peptide

Faller P, Hureau C, Berthoumieu O.

Inorg Chem. 2013 Nov 4;52(21):12193-206. doi: 10.1021/ic4003059. Epub 2013 Apr 22.

Concentration of donepezil to the cognitive response in Alzheimer disease

Yang YH, Chen CH, Chou MC, Li CH, Liu CK, Chen SH.

J Clin Psychopharmacol. 2013 Jun;33(3):351-5. doi: 10.1097/JCP.0b013e31828b5087.

Development and mechanism of γ-secretase modulators for Alzheimer's disease

Crump CJ, Johnson DS, Li YM.

Biochemistry. 2013 May 14;52(19):3197-216. doi: 10.1021/bi400377p. Epub 2013 May 2.

Targeted drug delivery across the blood brain barrier in Alzheimer's disease

Rocha S.

Curr Pharm Des. 2013;19(37):6635-46. doi: 10.2174/13816128113199990613.

CSF biomarker variability in the Alzheimer's Association quality control program

Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Kaeser SA, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman RA, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K; Alzheimer's Association QC Program Work Group.

Alzheimers Dement. 2013 May;9(3):251-61. doi: 10.1016/j.jalz.2013.01.010.

Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease

Jia JY, Zhao QH, Liu Y, Gui YZ, Liu GY, Zhu DY, Yu C, Hong Z.

Acta Pharmacol Sin. 2013 Jul;34(7):976-82. doi: 10.1038/aps.2013.7. Epub 2013 Apr 29.

Neuropeptides in Alzheimer's disease: from pathophysiological mechanisms to therapeutic opportunities

Van Dam D, Van Dijck A, Janssen L, De Deyn PP.

Curr Alzheimer Res. 2013 Jun;10(5):449-68. doi: 10.2174/1567205011310050001.

On the interaction of β-amyloid peptides and α7-nicotinic acetylcholine receptors in Alzheimer's disease

Oz M, Lorke DE, Yang KH, Petroianu G.

Curr Alzheimer Res. 2013 Jul;10(6):618-30. doi: 10.2174/15672050113109990132.

[Autumnal edition in the spring]

Meyer G.

Pflege Z. 2013 Apr;66(4):193.

Effectiveness and safety of memantine treatment for Alzheimer's disease

Yang Z, Zhou X, Zhang Q.

J Alzheimers Dis. 2013;36(3):445-58. doi: 10.3233/JAD-130395.

Adherence to cholinesterase inhibitors in Alzheimer's disease: a review

Brady R, Weinman J.

Dement Geriatr Cogn Disord. 2013;35(5-6):351-63. doi: 10.1159/000347140. Epub 2013 Apr 19.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias